Abstract

Hims & Hers Health Inc. will report quarterly results on May 11, 2026 Post Market, and investor attention is centered on whether revenue growth near mid-teens and an EPS trough can align with the company’s platform initiatives and recently strengthened branded weight-management offering.

Market Forecast

Consensus expects Hims & Hers Health Inc. to deliver 616.85 million US dollars in revenue this quarter, up 14.61% year over year, with adjusted EPS near 0.04 US dollars, down 64.16% year over year, and EBIT about 12.19 million US dollars, down 63.10% year over year. Sequentially, revenue would be essentially flat against last quarter’s 617.82 million US dollars, implying that mix, operating spending, and any GLP-1 product transition costs will be the pivotal drivers of earnings. The company’s core online channel remains the backbone of results, with the last reported quarter indicating an estimated 608.29 million US dollars from the online business and 9.52 million US dollars from wholesale, reinforcing platform-led monetization through subscriptions and cross-sell. The most promising near-term growth vector is the weight-management therapeutics offering, which underpins the projected 14.61% year-over-year revenue increase this quarter as branded GLP-1 availability on the platform ramps; while the company doesn’t break out a separate GLP-1 revenue line, total growth signals robust demand.

Last Quarter Review

In the prior quarter, Hims & Hers Health Inc. posted 617.82 million US dollars in revenue, up 28.41% year over year, a 71.94% gross profit margin, GAAP net income attributable to the parent of 20.60 million US dollars and a 3.33% net profit margin, with adjusted EPS of 0.08 US dollars, down 27.27% year over year. A key financial highlight was the quarter-on-quarter recovery of net income, which increased by 30.60%, reflecting improved operating leverage off a high-70s gross margin base despite a normalization in EPS year over year. The main business mix remained dominated by the online channel at an estimated 608.29 million US dollars (98.46% of last quarter revenue), complemented by wholesale at roughly 9.52 million US dollars (1.54%), indicating continued platform density where subscription breadth and cross-category adoption sustain top-line momentum.

Current Quarter Outlook

Core Online Subscriptions and Cross-Sell Engine

The online channel continues to anchor results, and this quarter’s near-flat sequential revenue set-up (616.85 million US dollars forecast vs 617.82 million US dollars last quarter) suggests management’s focus is less on absolute volume swings and more on the quality of growth. Expect attention on net new subscriptions, cross-sell penetration, and retention, as these levers drive the sustainability of revenue and predictability of cohort cash flows. Given the 71.94% gross margin last quarter, investors will gauge whether the company can keep gross margin in the low-70s while absorbing product mix changes tied to branded GLP-1 onboarding and any associated cost-of-sales shifts. Marketing efficiency remains a central theme for the model this quarter. If customer acquisition costs continue to normalize and payback periods stay within management’s targeted ranges, the company can defend EBITDA and EPS even as it supports branded therapeutic expansion. Conversely, a heavier mix of growth investments around weight-management could keep EBIT constrained near the 12.19 million US dollars estimate and EPS at roughly 0.04 US dollars, consistent with the forecast for a year-over-year EPS decline of 64.16%. The subscription engine’s ability to integrate new clinical offerings is central to monetization. A consistent cadence of cross-sell to existing members, expansion in average revenue per user, and reduced churn would offset any seasonal moderation and cushion earnings against the projected year-over-year compression in EBIT. The market will look for qualitative commentary on funnel conversion, repeat purchase rates, and unit economics to validate the stability implied by the flat quarter-on-quarter revenue outlook.

Weight-Management Therapeutics Momentum and Mix

The weight-management category is positioned as this quarter’s most consequential growth catalyst. The platform’s availability of branded GLP-1 medications is expected to support the 14.61% year-over-year revenue increase forecast for the quarter by improving conversion for patients who prefer FDA-approved, brand-name therapies and by broadening the appeal of telehealth for chronic-condition management. The evolving product mix has earnings implications: while branded therapeutics may compress gross margin versus compounded alternatives, they reduce regulatory and legal overhang and may improve conversion and retention, thereby bolstering lifetime value. Investors should expect management to update on prescription volumes, member uptake, and fulfillment reliability in this category, since supply continuity and formulary breadth directly influence revenue realization. Strong GLP-1 engagement can elevate the online channel’s monetization, but it can also pull forward operating investments in care coordination, pharmacy services, and clinical support, which helps explain the forecasted year-over-year declines in EBIT (down 63.10%) and EPS (down 64.16%) as the company invests to cement long-term growth. In that context, sequentially stable revenue alongside materially lower year-over-year EPS suggests a transition period where platform scaling and category expansion are prioritized over short-term margin maximization. The core question for this quarter is how efficiently the company can onboard and service GLP-1 demand while protecting the low-70s gross margin achieved last quarter. If the mix shift stabilizes and brand partnerships streamline cost-to-serve, the company can set the stage for operating leverage in subsequent quarters, especially if churn remains controlled and cross-sell into adjacent care categories continues to climb. Commentary on potential second-half revenue reacceleration, given current-quarter investment, will be closely parsed.

Key Stock Drivers to Watch This Quarter

Guidance framework and narrative will likely be the main swing factors for the stock reaction on May 11, 2026. With consensus revenue at 616.85 million US dollars, investors will evaluate the quality of growth: unit economics, marketing efficiency, and conversion rates in GLP-1, rather than a high headline beat. The relationship between gross margin durability and the shift toward branded medications is the most direct bridge between top-line momentum and EPS normalization beyond this quarter. Subscriber metrics will anchor the bull-bear debate. Acceleration in net member adds or improved retention would support the notion that the platform can expand wallet share even as it transitions product mix, de-risking the earnings path into the second half. On the other hand, any signs of churn pressure or elevated acquisition costs could cap EBIT upside near the 12.19 million US dollars estimate and keep EPS near the 0.04 US dollars forecast. Execution around fulfillment and clinical operations matters as much as demand. The cadence of GLP-1 prescriptions, speed of onboarding, and any updates on branded availability can influence both realized revenue and cost-to-serve in the quarter. Investors will also look for clarity on how quickly the mix shift can convert into improved operating leverage, and whether management signals a path from this quarter’s forecast trough in EPS to a steadier climb as revenue scales against relatively fixed overhead in the back half of the year.

Analyst Opinions

The balance of recent institutional commentary is predominantly positive, with a clearly bullish tilt. Among tracked views since January 1, 2026 and up to May 4, 2026, the ratio of bullish to bearish opinions is approximately 4:1, indicating around 80% of the views are constructive on Hims & Hers Health Inc. The majority thesis centers on the platform’s ability to monetize a larger addressable patient base as branded weight-management therapies expand on-platform, while the transition away from compounded-only offerings reduces regulatory and legal uncertainty and supports a cleaner, more durable growth profile. JPMorgan initiated coverage with an Overweight rating and a 35 US dollars price target in late April 2026, framing a catalyst path around a more stable GLP-1 business on-platform, potential regulatory clarity that expands the peptide category, reacceleration of revenue in the second half, and the possibility of additional branded partnerships. This viewpoint aligns with the quarter’s setup: revenue is expected to grow 14.61% year over year to 616.85 million US dollars, while EPS reflects deliberate investment to support long-lived customer relationships and clinical infrastructure. The constructive stance assumes that branded availability can lift conversion and retention, partly offsetting near-term EPS headwinds tied to mix and growth spending. Barclays’ Glen Santangelo maintained a Buy rating in late March 2026 with a 48 US dollars price target, emphasizing the durability of the company’s product roadmap and the operating leverage potential as the platform scales. From this vantage point, last quarter’s 71.94% gross margin and the dominance of the online channel (an estimated 608.29 million US dollars of revenue in the period) provide a solid foundation for margin stability while expanding in higher-demand categories such as GLP-1. The bank’s constructive case implicitly tolerates short-term EPS pressure when accompanied by evidence that unit economics remain sound—specifically, stable payback periods, robust conversion in the weight-management funnel, and improving cross-sell penetration. Canaccord Genuity’s Maria Ripps has reiterated a Buy rating through the spring of 2026, underscoring that the partnership path with a leading GLP-1 manufacturer reduces legal overhang and supports further multiple expansion as investors gain confidence in the platform’s compliance posture and scalability. This perspective resonates with the current quarter’s forecasts: EBIT is expected at 12.19 million US dollars, down 63.10% year over year, reflecting upfront investments and mix shifts rather than deterioration in underlying demand. The constructive framework expects these investments to translate into higher-quality growth, enhanced lifetime value per member, and widening platform adoption across categories. Taken together, the majority view posits that this quarter is a bridge: revenue growth remains solid at 14.61% year over year, while earnings reflect the costs of aligning the platform to branded medications and a broader clinical experience. Bulls will gauge success along three vectors: evidence that GLP-1 on-platform is scaling with stable fulfillment; confirmation that gross margin remains near the low-70s zone despite mix changes; and signs of operating leverage in the outlook that point to EPS normalization beyond this quarter. If management presents a credible path that ties these elements to second-half reacceleration, the majority opinion suggests the stock reaction could hinge less on small revenue variances and more on the clarity and durability of the growth and margin trajectory.